Dr. Cabanillas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2007 - 2009
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1998 - 2001
- University of Puerto Rico School of MedicineClass of 1998
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2022 - 2026
- GA State Medical License 2023 - 2026
- TN State Medical License 2022 - 2026
- TX State Medical License 2001 - 2026
- WA State Medical License 2022 - 2026
- AL State Medical License 2023 - 2025
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Clinical Trials
- A Study of Actonel for the Prevention of Bone Loss Start of enrollment: 2004 Feb 01
- The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Start of enrollment: 2012 Nov 01
- Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
- Join now to see all
Publications & Presentations
PubMed
- [18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy.Samir A Dagher, Kim O Learned, Richard Dagher, Jennifer Rui Wang, Xiao Zhao
AJNR. American Journal of Neuroradiology. 2024-11-21 - Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer.Julianna K Bronk, Alexander Augustyn, Abdallah S R Mohamed, C David Fuller, Adam S Garden
Radiotherapy and Oncology. 2024-11-01 - 1 citationsAnti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Maria E Cabanillas, Ramona Dadu, Renata Ferrarotto, Maria Gule-Monroe, Suyu Liu
JAMA Oncology. 2024-10-24
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah,..., The New England Journal of Medicine
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineThinh Vu, Naifa L Busaidy, Maria E Cabanillas, Steven G Waguespack, Steven I Sherman, Mark Zafereo, The Journal of Clinical Endocrinology and Metabolism
- Selective RET Kinase Inhibition for Patients with RET-Altered CancersL J Wirth, N L Busaidy, M E Cabanillas, Annals of Oncology
Lectures
- New Medical Options for the Treatment of Advanced Thyroid CancerENDO 2019 - New Orleans, LA - 3/24/2019
- Advanced Thyroid Cancers: New Insights and TreatmentsENDO 2019 - New Orleans, LA - 3/25/2019
- From Thyroid Nodules to Thyroid Cancer: Diagnosis and TreatmentENDO 2019 - New Orleans, LA - 3/25/2019
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
- Pembrolizumab Boosts Survival in Anaplastic Thyroid CancerNovember 5th, 2024
- Atezolizumab plus Targeted Agents Shows Promise in Anaplastic Thyroid CarcinomaOctober 28th, 2024
- New Hope Against a Rare, Aggressive Form of Thyroid CancerOctober 28th, 2024
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: